SNX 2112 | PF-04928473
SNX 2112 | PF-04928473
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
5 mg 10 mg 50 mg
Product Availability
3-5days
Price
$166.00
Member price
Product Availability
3-5days
Price
$246.00
Member price
Product Availability
3-5days
Price
$666.00
Member price
Quantity
- +
Product Overview
Product Name SNX 2112 | PF-04928473
CAS908112-43-6
FormulaC23H27F3N4O3
MW464.48
AppearanceWhite to off-white powder
Storage conditionStore in a dry and dark sealed container, short-term (weeks to months) storage at 0-4 ℃, long-term (months to years) storage at -20 ℃.
Security information
Product details

 SNX-2112, also known as PF 04928473, is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGFR, and AKT as well as abrogation of Ras/Raf/MEK/MAPK and PI3K/AKT signaling, followed by complete cell cycle arrest.

Related
Sorry, no related items
History
Alacizumab (Anti-VEGFR2 / KDR / CD309)
Benralizumab (Anti-IL-5Ra/ CD125)
Anti-Human IL-23 Monoclonal Antibody(Guselkumab)
SNX 2112 | PF-04928473
Pinobanksin 3-acetate ((2R,3R)-Pinobanksin 3-acetate; Pinobanksin 3-O-acetate; Pinobanksin acetate)
Lerdelimumab
Sunitinib | Sunitinib Base
Anti-Human BCMA Monoclonal Antibody(Belantamab biosimilar) mAb; GSK2857914
HCTU; O-(6-Chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium Hexafluorophosphate/O-(6-Chloro-1-hydrocibenzotriazol-1-yl)- -1,1,3,3-tetramethyluroniumhexafluorophosphate
Artesunate